Category Archives for "Press Releases"

0 Global Stem Cells Group Names BIOMEN S.A as exclusive Representative in Costa Rica

Global Stem Cells Group, Inc., has named neurologist and anti-aging specialist Dra. Mariella Tanzi, founder of BIOMEN S.A, to be the exclusive representative for Global Stem Cells Group in the Costa Rica territory. Tanzi will also open a new Cellgenic clinic in the Costa Rican capital of San Jose.

Global Stem Cells Group, Inc. has signed BIOMEN S.A and its founder, anti-aging and regenerative medicine specialist Dra. Mariella Tanzi, to represent the Miami-based stem cell company as an exclusive representative for the Costa Rican territory. Tanzi will also open a new Cellgenic clinic in the Costa Rican capital of San Jose.

The arrangement is part of the Global Stem Cells Group’s global expansion program, which requires affiliate representatives to have more than five years experience in the health care industry with at least some experience in regenerative medicine.

Tanzi will be instrumental in helping to manage the company’s growth in Costa Rica. Her responsibilities will include arranging a number of stem cell training courses at the Cellgenic facility in Costa Rica over a one-year period, certification of physicians, and willingness to organize an annual stem cell and regenerative medicine symposium in their territory.

“Our main focus is to organize Costa Rica’s first annual symposium on stem cells and regenerative medicine in 2015,” says Global Stem Cells Group Founder Benito Novas. “This new alliance will allow us to establish Cellgenic as a leader in regenerative medicine therapies in Costa Rica.”

0 Maritza Novas, R.N., M.S.N and Alfredo Hoyos, M.D. to Speak at the EuroMedicom Aesthetic & Anti-Aging Medicine World Congress – Latin America, Nov. 27, 28 and 29, 2014

Global Stem Cells Group will be represented at the First AMWC Latin America Aesthetic & Anti-aging Medicine World Congress in Medellin, Colombia by Maritza Novas, R.N., M.S.N. and Stem Lab Founder Alfredo Hoyos, M.D. Novas and Hoyos are scheduled to speak on non-invasive aesthetic medicine techniques.

Global Stem Cells Group has announced that Alfredo Hoyos, M.D. and Maritza Novas, R.N., M.S.N. will be speaking at the EuroMedicom First AMWC Latin America Aesthetic & Anti-aging Medicine World Congress in Medellin, Colombia, Nov. 27, 28 and 29, 2014.

The World Congress Colombia event is organized in cooperation with the International Scientific Board of the AMWC Monaco event, the largest international event in the field of aesthetic and anti-aging medicine. The goal of the event is to showcase the AMWC’s commitment to innovation, expertise and excellence in aesthetic and anti-aging medicine, and to share a wealth of experience and teaching skills with attendees from around the world.

In addition to keeping up with worldwide practices, the Medellin conference is designed to contribute to enhancing practitioners’ skills through advanced academic and clinical sessions, as well as lectures presented by prominent experts in the field like Hoyos and Novas.

Novas and Hoyos will discuss the latest advancements in stem cell medicine for cosmetic and anti-aging applications. Hoyos, founder of Stem Lab, Global Stem Cells Group’s new representative in Colombia, will also discuss plans to hold a symposium on stem cell and regenerative medicine in Bogota in Feb., 2014.

Novas is a lead trainer and part of the research and development team for Stem Cell Training, a Global Stem Cells Group subsidiary. Hoyos, a prominent Colombian plastic surgeon, is the world-renowned creator of high-definition liposculpture and other advanced body contour techniques. Hoyos will also be promoting the new collaboration between Global Stem Cells Group and his Colombia-based Stem Lab biotechnology company, which develops stem cell techniques for regenerative medicine treatments.

Hoyos serves Global Stem Cells Group and its subsidiary Cellgenic as exclusive representative for the Colombian territory. Hoyos will be in charge of all Global Stem Cells Group divisions and programs in Colombia, including patient recruiting through Cellgenic, physician training and certification trough Stem Cell Training, and stem cell equipment and disposables sales through Adimarket. Five dates are planned for training and physician certification under the Global Stem Cells Group brand in Colombia during 2015.

0 Global Stem Cells Group Signs Prominent Plastic Surgeon Alfred Hoyos, M.D., Creator of High Definition Liposculpture

Global Stem Cells Group, Inc., has signed prominent Colombian plastic surgeon and Stemlab.com founder Alfredo Hoyos, M.D. to represent the Miami-based regenerative medicine company in Colombia.

Global Stem Cells Group, Inc. has signed Stemlab.com founder and prominent plastic surgeon Alfredo Hoyos, M.D. to represent the Miami-based stem cell company as an exclusive representative for the Colombian territory. Hoyos is the world-renowned creator of high-definition liposculpture and other advanced body contour techniques.

Hoyos will join Kristin Comella, Chief Scientific Officer of BioHeart, Inc., to combine his Stemlab medical team with her regenerative medicine protocols to promote research and cutting-edge stem cell technology in Colombia. In addition, Hoyos and Comella will team up in 2005 to provide five stem cell training sessions to medical professionals in Colombia, and establish the country’s first symposium on stem cell therapies and regenerative medicine.

Global Stem Cells Group searches the globe for innovative stem cell practitioners that fit in with the Colombian markets. Hoyos will be in charge of all Global Stem Cells Group divisions and programs in Colombia, including patient recruiting through Cellgenic, physician training and certification trough Stem Cell Training, and stem cell equipment and disposables sales through Adimarket.

Cellgenic, Stem Cell Training and Adimarket are regenerative medicine companies under the Global Stem Cells Group brand.

“Our main objective is to organize Colombia’s first symposium on stem cells and regenerative medicine in 2015,” says Global Stem Cells Group Founder Benito Novas. “Our new alliance with Dr. Hoyos and StemLab.com will allow us to establish our brand as the leader in regenerative medicine therapies in Colombia.”
Global Stem Cells Group’s strategy is to expand into foreign markets by recruiting local representatives and distributors like Hoyos to help manage the company’s growth in a specific geographic area. Global Stem Cells group requires any company under consideration for the expansion program to have more than five years experience in the health care industry with at least some experience in the field of regenerative medicine.

In addition, geographic alliances require a commitment to a number of stem cell training courses during a one-year period, certification of physicians, and willingness to organize a large medical meeting or symposium in their territory.

About Alfredo Hoyos, M.D.:
Colombia-based plastic surgeon Alfredo Hoyos, M.D. takes advantage of his talent as a painter and sculptor to perform high-definition liposculpture, giving his patients athletic-looking bodies with minimal scarring. The creator of high-definition liposculpture and other advanced body contour techniques, Hoyos combines his expertise in regenerative medicine therapies with other technologies to achieve spectacular results in aesthetic and anti-aging medicine.

Hoyos is the founder of Stemlab, a biotechnology company committed to developing new techniques using (stromal) stem cells derived from adipose tissue to improve the quality of life for people.

About BioHeart, Inc.:
Bioheart, Inc. is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues.
Bioheart’s goals are to cause damaged tissue to be regenerated, when possible, and to improve a patient’s quality of life and reduce health care costs and hospitalizations.

Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. Its leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient’s heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. For more information on Bioheart, visit http://www.bioheartinc.com, or visit us on Facebook: Bioheart and Twitter @BioheartInc.

About Stemlab:
Stemlab is an innovative biotechnology company that aims to fill gaps in the processing and handling of stem cells derived from stromal adipose tissue using the latest technologies in regenerative medicine. The goal is to expand the therapeutic arsenal to increase the options in the treatment of chronic diseases and improve every patient’s quality of life.

0 Global Stem Cells Group Announces Accredited Online Stem Cell Training Course

Global Stem Cell Group subsidiary Stem Cell Training, Inc. has announced the release of its new online accredited stem cell training course that can be completed from the home or office.

GlobalStemCellsGroup.com, its subsidiary Stem Cell Training, Inc. and Bioheart, Inc. have announced a new 16 CME online credit course for physicians. Working at their own pace from the privacy of home or office, physicians can learn how to implement regenerative medicine techniques in their own practices.

Taught by stem cell and regenerative medicine expert Kristin Comella, the online course provides didactic lectures on regenerative medicine and scientifically validated protocols. Lecture topics include:
Stem cell biology
Regulatory environment
Platelet-rich plasma
Induced pluripotent stem cells
cGMPs for stem cell therapies
Embryonic stem cells
Bone Marrow stem cells
Adipose derived stem cells
Harvesting and isolation of adipose derived stem cells
Harvesting and isolation of bone marrow stem cells

Included in the online coursework are training videos, training booklets, detailed protocols and power point presentations with instructions and images for:
Adipose extraction
Adipose stem cell isolation
Bone marrow stem cell isolation
Platelet rich plasma
Patient forms and guidelines (including editable and non-editable confidential medical history for pre- and post-medical instruction, safety guidelines for harvesting adipose tissue, blood work request flyer and confirmation of treatment detailer)
Sample informed consent forms (for adipose derived stem cells, bone marrow derived stem cells and platelet-rich plasma)
Stem Cell Banking with flyers for physicians and patients, as well as stem cell banking requests for cryopreservation
Stem cell training lecture notes
Access to regenerative medicine experts
Medical professionals can also choose to combine the online coursework with one-on-one training with a regenerative medicine specialist.
For more information, visit the Global Stem Cells website,, email bnovas(at)stemcellsgroup(dot)com, or call 305-560-5337.

About Kristin Comella:
Kristin Comella has more than 15 years’ experience in corporate entities with expertise in regenerative medicine. Comella has pioneered a variety of stem cell therapies including cord blood derived cells, bone marrow cells, muscle cells and adipose cells for use in many different applications. As Chief Scientific Officer for Bioheart, Inc., Comella has developed a wide range of regenerative products and techniques that have been successfully implemented into the clinic, and has led her team to earn the first ever FDA approval for clinical trials using a combined cell and gene therapy product.
Bioheart is a publicly traded company focusing on the discovery, development and commercialization of autologous cell therapies for the treatment of degenerative diseases. Since joining Bioheart in 2004, Comella has played a major role in managing the product development, manufacturing and quality systems of cellular products. Comella currently and actively serves on multiple boards in the stem cell arena. She joined forces with Global Stem Cells Group and its subsidiary Stem Cells Training in 2013 to design and lead intensive, hands-on stem cell training courses to industry professionals in the U.S. and abroad.

0 Global Stem Cells Group Teams With CordónVida Servet Stem Cell Bank and Clinic to Organize the First International Symposium on Stem Cells and Regenerative Medicine

Global Stem Cells Group announced plans to team with Servet CordónVida Stem Cell Bank and Clinic in Santiago, Chile to organize the First International Symposium on Stem Cells and Regenerative Medicine. The symposium will be held at the InterContinental Hotel in Santiago Sept. 26, followed by an intensive, two-day hands-on training course in stem cell harvesting, isolation and applications Sept. 27 and 28 at the CordónVida Clinic.

Global Stem Cells Group and the Servet CordónVida Stem Cell Bank Clinic of Chile will be teaming up to organize the First International Symposium on Stem Cells and Regenerative Medicine in Santiago, Chile Sept. 26, 27 and 28. The three-day symposium will be followed by an intensive hands-on training course at the Servet Clinic for medical practitioners interested in learning techniques for harvesting stem cells for in-office medical therapies.
Symposium organizers plan to initiate a dialogue between researchers and practitioners to bridge the gap between “bench” science—research science that is exclusively conducted in a lab setting—and stem cell therapies delivered in the physician’s office.

The first-of-its-kind conference will host some of the world’s leading experts on stem cell research and therapies. Servet CordónVida General Manager Mauricio Cortes, Ph.D. says that Santiago is the perfect launching pad for the event, as awareness and increasing demand for stem cell services has swept the South American country’s healthcare market over the past decade.

“The use of human stem cells in medical therapies has attracted major scientific and public attention because stem cells are pluripotent, meaning they have the ability to differentiate into all body tissues,” Cortes says. “Knowing this, the possibilities for regenerating damaged or diseased tissue where no effective treatments existed before opens a new world of possibilities to patients and healthcare providers.
“We’re very excited to participate in this important conference.”

Servet CordónVida is a private umbilical cord blood bank that harvests and stores the hematopoietic-rich blood stem cells found in all newborns’ umbilical cords after birth. The hematopoietic tissue is responsible for the renewal of all components of the blood (hematopoiesis) and has the ability to regenerate bone marrow and restore depressed immune systems.

Umbilical (UCB) stem cells offer a wealth of therapeutic potential because they are up to 10 times more concentrated than bone marrow stem cells. In addition, UCB cells have a generous proliferative capacity with therapeutic potential that is very similar to embryonic stem cells, without the ethical debate associated with embryonic stem cell research and use.

Perhaps most significant is the fact that UCB cells are the purest adult stem cells available, coming from newborns who have not been exposed to disease or external damage. Many parents today are utilizing cord banks like Servet CordónVida to store their newborn’s UCB cells safely for future medicinal use if the need arises.

“Thanks to advances in stem cell science, we can preserve an infant’s stem cells at birth and store them safely for his or her future,” says CordónVida Director Javier Sáez. “Hopefully, this symposium will be the first of many like it in the future of regenerative medicine, because the more we discuss what we know about the power of stem cells to heal, the closer we get to sparing our patients from needless suffering when the cure is right before us.”

Global Stem Cells Group and Servet CordónVida represent a growing global community of committed stem cell researchers, practitioners and investors whose enthusiasm is a direct result of the hundreds of diseases and injuries that stem cell therapies are curing every day, and the list keeps growing. Global Stem Cell Group’s First International Symposium on Stem Cell Research and Regenerative Medicine will host experts from the U.S., Mexico, Greece, Hong Kong and other regions around the globe who will speak on the future of regenerative medicine and share experiences in their field of specialty. The Global Stem Cells Group Symposium is seeking to open lines of communication and cooperation, explore new and exciting techniques in stem cell therapy, and create an environment of education and learning.

The symposium will be held at the Santiago InterContinental Hotel. For more information on the symposium and the lineup of guests and speakers already confirmed, visit the First International Stem Cells and Regenerative Medicine website.

About Servet CordónVida Bank Stem Cell Clinic:
Servet CordónVida General Manager Mauricio Cortes, PhD, Director Javier Sáez and the team of team of highly skilled and committed practitioners are dedicated to sharing the known benefits and potential benefits of stem cell medicine with parents and patients both in Chile and abroad.

Servet CordónVida offers cutting edge technology in cryopreservation and storage of stem cells on behalf of parents and patients who understand the benefits of having their own stem cells available to meet possible future medical needs.

0 Global Stem Cells Group to Hold Intensive, Two-day Training Course on Stem Cell Harvesting, Isolation and Re-integration Sept. 27 and 28 Following International Symposium

Global Stem Cells Group announced plans to hold a two-day, hands-on intensive stem cell training course at the Servet Clinic following the First International Symposium on Stem Cells and Regenerative Medicine in Santiago Chile, Sept. 26, 27 and 28, 2014.

Global Stem Cells Group, its subsidiary Stem Cell Training, Inc. and Bioheart, Inc. have announced plans to conduct a two-day, hands-on intensive stem cell training course at the Servet CordónVida Clinic Sept. 27 and 28 in Santiago, Chile. The “Adipose Derived Harvesting, Isolation and Re-integration Training Course,” will follow the Global Stem Cells Group First International Symposium on Stem Cells and Regenerative Medicine at the Santiago InterContinental Hotel Sept. 26, 2014.

Global Stem Cells Group and the Servet CordónVida Stem Cell Bank Clinic of Chile are co-organizing the symposium, designed to initiate a dialogue between researchers and practitioners and share the expertise of some of the world’s leading experts on stem cell research and therapies.

Servet CordónVida is a private umbilical cord blood bank that harvests and stores the hematopoietic-rich blood stem cells found in all newborns’ umbilical cords after birth. The hematopoietic tissue is responsible for the renewal of all components of the blood (hematopoiesis) and has the ability to regenerate bone marrow and restore depressed immune systems.

Umbilical (UCB) stem cells offer a wealth of therapeutic potential because they are up to 10 times more concentrated than bone marrow stem cells. In addition, UCB cells have a generous proliferative capacity with therapeutic potential that is very similar to embryonic stem cells, without the ethical debate associated with embryonic stem cell research and use.

UCB cells are the purest adult stem cells available, coming from newborns who have not been exposed to disease or external damage. Many parents today are utilizing cord banks like Servet CordónVida to store their newborn’s UCB cells safely for future medicinal use if the need arises.

Global Stem Cells Group and Servet CordónVida represent a growing global community of committed stem cell researchers, practitioners and investors whose enthusiasm is a direct result of the hundreds of diseases and injuries that stem cell therapies are curing every day. Global Stem Cell Group’s First International Symposium on Stem Cell Research and Regenerative Medicine will host experts from the U.S., Mexico, Greece, Hong Kong and other regions around the globe who will speak on the future of regenerative medicine and share experiences in their field of specialty. The Global Stem Cells Group is hoping the symposium will open lines of communication and cooperation, explore new and exciting techniques in stem cell therapies, and create an environment of education and learning.

0 Global Stem Cells Group to Host the First International Symposium on Stem Cells and Regenerative Medicine in Buenos Aires, Argentina Oct. 2, 3 and 4, 2014

Global leaders in stem cell research and regenerative medicine will be converging on Buenos Aires, Argentina Oct. 2, 3 and 4 2014 for the first ever Global Stem Cells Symposium.

GlobalStemCellsGroup.com will host the First International Symposium on Stem Cell Research in Buenos Aires, Argentina Oct. 2, 3 and 4. The symposium will provide an opportunity to showcase advancements in stem cell research and therapies on a global level and establish a dialogue among the world’s leading stem cell experts. Pioneers and luminaries in stem cell medicine will be featured speakers as well as accomplished guests prepared to share their knowledge and experience in their individual medical specialties.

Regenerative medicine as a field is still in its infancy, and Global Stem Cells Group President and CEO Benito Novas believes it is time to clear up old misconceptions and change outdated attitudes by educating people on the wide range of illnesses and injuries stem cell therapies are already treating and curing. The first step, Novas says, is establishing a dialogue between researchers and practitioners in order to move stem cell therapies from the lab to the physician’s office.

“Our objective is to open a dialogue among the world’s medical and scientific communities in order to advance stem cell technologies and translate them into point-of-care medical practices,” Novas says. “Our mission is to bring the benefits of stem cell therapies to the physician’s office for the benefit and convenience of the patient, safely and in full compliance with the highest standard of care the world has to offer.”
An interdisciplinary team of leading international stem cell experts will provide a full day of high-level scientific lectures aimed at medical professionals.

Among the growing list of speakers are some of the world’s most prominent authorities on stem cell medicine including:
Kristin Comella, M.A.,CEO and Chief Scientific Officer of Bioheart, Inc.
Vasilis (Bill) Paspaliaris, M.D., Director and founder of Adistem Ltd.
David B Harrell, PhD, founder and CEO Harrell Biosciences Consulting
Joseph Purita, M.D., Medical Director of the Institute of Regenerative and Molecular Orthopaedics in Boca Raton, Florida.
Todd Malan, M.D., founder of the Innovative Cosmetic Surgery Center and the Center for Regenerative Cell Medicine, Washington DC

The objective of Global Stem Cell Group’s international symposium is to educate the public and the medical community, and at the same time establish a dialog between physicians, scientists, biotech companies and regulatory agencies in order to advance stem cell technologies so they can be used to benefit people who need them.

Global Stem Cells Group is also joining forces with some of the most prestigious regenerative medicine conferences in South America including:
XVI Latin American Congress of Cosmetic and Aesthetic Surgery, Buenos Aires presided by Professor Julio Ferreira
XIX Congress of Orthopedics and Musculoskeletal Medicine, Rio de Janeiro, Brazil.

Stem cell therapies are revolutionizing the anti-aging aesthetics industry while offering new hope for sufferers of serious chronic debilitating diseases
For more information on the Global Stem Cell Group First International Symposium on Stem Cells and Regenerative Medicine and the event’s lineup of speakers, visit the Global Stem Cells Symposium website.

0 Global Stem Cells Group and Revita Life Sciences Announce Joint Venture to Establish a Stem Cell Training Course in Delhi, India

Global Stem Cells, Inc. has announced plans to establish a stem cell training course in Dehli, India, in collaboration with Revita Life Sciences of Dehli, May 22 and 23.

GlobalStemCellsGroup.com and Revita Life Sciences have announced plans to present the adipose and bone marrow stem cells course hosted by Himanshu Bansal, M.D., May 22-23 in Delhi.

Revita Life Sciences is a biotech company based in Dehli that specializes in stem cell research, training and clinical applications protocol development in regenerative medicine. Stem Cell specialists from both Global Stem Cells Group and Revita will participate in the two-day training program designed to help medical professionals bring stem cell therapies to the physicians’ office.

The adipose-derived harvesting, isolation and re-integration training course for the advancement of stem cell procedures is a two-day, hands-on intensive training course developed for physicians and high-level practitioners to learn techniques in harvesting and reintegrating stem cells derived from adipose (fat) tissue and bone marrow. The objective of the training is to bridge the gap between bench science in the laboratory and the doctor’s office by teaching effective “in office“ regenerative medicine techniques.

About Revita Life Science:
Revita Life Sciences is a biotechnology company that provides complete support to patients from their first inquiry through stem cell therapy performed by a Revita Life Science specialized physician.
Revita’s primary objective is the development of stem cell therapies that target areas of significant unmet or poorly met medical need. Years of research and experience have resulted in substantial improvements in the health and condition of patients suffering from a variety of illnesses through stem cell therapy, even where other treatments have failed.

Revita Life Sciences’ skilled team of physician use fresh, biologically intact stem cells extracted directly from the patient (autologous adult stem cells) to eliminate any risk of rejection. The result is personalized stem cell therapy created especially for them.

Revita Life Sciences is carrying out research, training and clinical applications-protocol development in regenerative medicine, with emphasis on autologous adult stem and progenitor cells possessing regenerative capabilities for clinical application. For more information, visit the Revita Life Sciences website.

0 Global Stem Cells Group, Inc. and BioHeart, Inc. Launch Clinical Trial for COPD Stem Cell Therapies

Global Stem Cells Group and Bioheart announce the launch of a unique clinical trial called “Adipose Derived Cells for Chronic Obstructive Pulmonary Disease.”

Global Stem Cells Group, Inc. and BioHeart, Inc. announce the launch of a clinical trial for the treatment of Chronic Obstructive Pulmonary Disease (COPD) using adipose-derived stem cell technology. The clinical trials will be held at the Global Stem Cells treatment center in Cozumel, Mexico, as well as in several U.S. states. Global Stem Cells Group affiliate Cellgenic in collaboration with CMC Hospital of Cozumel offer cutting-edge cellular medicine treatments to patients from around the world.

The study titled “An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered intravenously in Patients with Chronic Obstructive Pulmonary Disease” is lead by principal investigator Armando Pineda Velez, Global Stem Cells Group Medical Director. Global Stem Cells Group has represented that it offers the most advanced protocols and techniques in cellular medicine from around the world.

The Cozumel clinical trials will be lead by Rafael Moguel, M.D., an advocate and pioneer in the use of stem cell therapies to treat a wide variety of conditions.
COPD is one of more than 150 chronic conditions that are treatable with adult stem cells, eliminating the potential risk of surgery, transplants, and toxic drugs
Details of the protocol and eligibility criteria can be found on the government clinical trial website at: http://www.clinicaltrials.gov.

About Global Stem Cells Group:
Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions.

With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

Global Stem Cells Group’s corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCG’s six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments

About Bioheart:
Bioheart, Inc. is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues.
Bioheart’s goals are to cause damaged tissue to be regenerated, when possible, and to improve a patient’s quality of life and reduce health care costs and hospitalizations.

Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. Its leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient’s heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. For more information on Bioheart, visit http://www.bioheartinc.com.

0 Bioheart, Inc. and Global Stem Cells, Inc. Announce New Clinical Site in Mexico

Bioheart, Inc., in collaboration with Global Stem Cells, Inc. have initiated a new clinical site in Cozumel, Mexico.

Bioheart Inc., a biotech company focused on the discovery, development and commercialization of autologous cell therapies, has announced that it has initiated a new clinical site in collaboration with Global Stem Cell Group, Inc. in Cozumel, Mexico. The two companies successfully treated their first congestive heart failure patient at the new clinical site last week, using Bioheart’s AdipoCell (adipose derived stem cells).

The therapy involved the use of stem cells derived from the patient’s own fat (adipose tissue) obtained using liposuction. The recovered stem cells were injected into the patients’ heart with Bioheart’s MyoCath® needle injection catheter which allows for introduction of the cells directly into the heart without invasive surgery.

Rafael Moguel, M.D., Head of the Cardiac Program at the Centro Medico de Cozumel, was the treating interventional cardiologist for the Bioheart therapy procedure.
“Our center is very excited to participate in the cutting edge programs at Bioheart,” Moguel says. “We can offer new hope to patients suffering from debilitating diseases by utilizing regenerative medicine, and delivering them non-invasively into the heart.”

The MyoCath catheter was introduced using a radial artery approach, the first such documented stem cell case using this delivery method. The benefit of a radial artery approach is that it does not require the patient to lie flat for up to six hours, as in a femoral artery approach. Patients are able to sit up, walk and eat immediately following the procedure, and the risk of internal bleeding is eliminated.
Bioheart and Global Stem Cells Group have designed several different protocols to be utilized at the center in Cozumel, offering treatments to patients for a variety of different indications.

About Bioheart, Inc.:
Bioheart is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. Bioheart’s goals are to cause damaged tissue to be regenerated, when possible, and to improve a patient’s quality of life and reduce health care costs and hospitalizations.

Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. Its leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient’s heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. For more information on Bioheart, visit http://www.bioheartinc.com.